PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17164721-10 2006 Furthermore, CsA markedly impaired the immunosuppressive function of CD4CD25Treg cells. Cyclosporine 13-16 CD4 antigen Mus musculus 69-72 17164721-11 2006 CONCLUSIONS: CsA significantly impaired the development and function of CD4CD25Treg cells. Cyclosporine 13-16 CD4 antigen Mus musculus 72-75 17096891-5 2006 The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments. Cyclosporine 127-130 CD4 antigen Mus musculus 23-26 12698107-7 2003 In cyclosporine- or FK506-treated mice, T-cell proliferation was suppressed in the CD4 subset but not in the CD8 subset. Cyclosporine 3-15 CD4 antigen Mus musculus 83-86 16223671-4 2005 Using CD4(-/-) and CD8(-/-) mice, we established that CyA immunosuppression at this dose was only effective at preventing allograft vasculopathy in mice lacking CD8(+) T cells. Cyclosporine 54-57 CD4 antigen Mus musculus 6-9 16223671-11 2005 We interpret these data to suggest that in the face of CyA immunosuppression CD4(+) T cell effector function is ablated while CD8(+) T cell function remains partially intact. Cyclosporine 55-58 CD4 antigen Mus musculus 77-80 15788440-7 2005 It is surprising that the increased proliferation of CD4(+) T cells with a suppressive dose of Con A on blocking CTLA4-CD80/CD86 interactions is largely interleukin (IL)-2-independent but is cyclosporine A-sensitive. Cyclosporine 191-205 CD4 antigen Mus musculus 53-56 14688381-6 2004 Beginning on the day of bone marrow transplantation, groups of control and CsA-treated animals were treated with mAb against either CD4 or CD8 for 21 days. Cyclosporine 75-78 CD4 antigen Mus musculus 132-135 15147420-6 2004 Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset. Cyclosporine 79-82 CD4 antigen Mus musculus 120-123 15147420-6 2004 Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset. Cyclosporine 79-82 CD4 antigen Mus musculus 238-241 15147420-6 2004 Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset. Cyclosporine 79-82 CD4 antigen Mus musculus 120-123 15147420-6 2004 Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset. Cyclosporine 79-82 CD4 antigen Mus musculus 238-241 9566798-4 1998 In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte. Cyclosporine 95-98 CD4 antigen Mus musculus 129-132 10836388-0 2000 Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. Cyclosporine 34-46 CD4 antigen Mus musculus 114-117 8652191-11 1996 Thus, although CsA administration attenuated spleen cell activation and was associated with a marked attenuation of airway responsiveness in mice with genetically hyperresponsive airways, CD4+ and CD8+ T cells do not appear to mediate this response. Cyclosporine 15-18 CD4 antigen Mus musculus 188-191 9507739-7 1998 Furthermore, administration of cyclosporine and anti-CD8 monoclonal antibodies to II-4+ recipients prolonged xenograft survival to at least the same extent as allograft survival, demonstrating that the strength of cell-mediated xenograft rejection resides in the CD4+ indirect response. Cyclosporine 31-43 CD4 antigen Mus musculus 263-266 9434804-8 1998 Therefore, the use of a CD4-CDR3 peptide can complement and potentiate the immunosuppressive effects of CsA in the prevention of GVHD following allogeneic BMT. Cyclosporine 104-107 CD4 antigen Mus musculus 24-27 9249940-7 1997 When CyA treatment was continued throughout the period during which unresponsiveness to the graft is induced by anti-CD4 mAb therapy, 50% of the grafted hearts were rejected once the CyA was discontinued. Cyclosporine 5-8 CD4 antigen Mus musculus 117-120 7540861-5 1995 When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin. Cyclosporine 168-171 CD4 antigen Mus musculus 20-23 8828007-0 1996 Cross-linking the TCR complex induces apoptosis in CD4+8+ thymocytes in the presence of cyclosporin A. Cyclosporine 88-101 CD4 antigen Mus musculus 51-54 7594578-4 1995 Most of the TCR-alpha beta i-IEL whose development was inhibited by CSA belonged to the CD4-CD8+ alpha alpha subset. Cyclosporine 68-71 CD4 antigen Mus musculus 88-91 7798591-7 1994 Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets. Cyclosporine 119-122 CD4 antigen Mus musculus 202-205 7925567-9 1994 More strikingly, deletion of CD4+8+ thymocytes from BM3.3-Tg increased, whilst activation was partially inhibited by CsA. Cyclosporine 117-120 CD4 antigen Mus musculus 29-32 7798591-7 1994 Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets. Cyclosporine 119-122 CD4 antigen Mus musculus 219-222 7831928-0 1994 CD4+ and CD8+ cells in mice infected with Trichinella spiralis and treated with cyclosporine A. Cyclosporine 80-94 CD4 antigen Mus musculus 0-3 8033411-6 1994 After administration of CsA to newborn NOD mice, there was a reduction (P < 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased. Cyclosporine 24-27 CD4 antigen Mus musculus 93-96 8033411-6 1994 After administration of CsA to newborn NOD mice, there was a reduction (P < 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased. Cyclosporine 24-27 CD4 antigen Mus musculus 106-109 8033411-6 1994 After administration of CsA to newborn NOD mice, there was a reduction (P < 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased. Cyclosporine 24-27 CD4 antigen Mus musculus 106-109 8114793-6 1994 Cells expressing CD4 and CD8 antigens were observed in the injected muscles of mice treated with CsA alone. Cyclosporine 97-100 CD4 antigen Mus musculus 17-20 7831928-5 1994 It was found that the number of CD4+ cells in the control and in the CyA-treated mice was similar but in the animals receiving the drug the reaction was less intensive. Cyclosporine 69-72 CD4 antigen Mus musculus 32-35 34224738-8 2021 CsA suppressed activation of ITK in cultured CD4+ T cells and calcineurin-containing microclusters adjacent to the T cell receptor signaling complex. Cyclosporine 0-3 CD4 antigen Mus musculus 45-48 1282000-3 1992 Using this and immunohistochemical staining, we found that the immunosuppressants cyclosporin A and FK506 decreased CD4 expression in cultured murine microglia without causing any significant decrease in cell viability. Cyclosporine 82-95 CD4 antigen Mus musculus 116-119 1671051-7 1991 Although cyclosporin A inhibited CD4 cells to fragment target DNA during the early phase (90 min) of E:T interaction, this inhibition was not sustained in the later phase (210 min) of the assay. Cyclosporine 9-22 CD4 antigen Mus musculus 33-36 2228019-5 1990 It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant. Cyclosporine 130-133 CD4 antigen Mus musculus 140-143 2228019-6 1990 Thus, all of the TcR alpha beta-bearing cells, including CD4-8- cells but none of the TcR alpha beta- cells, are CsA sensitive. Cyclosporine 113-116 CD4 antigen Mus musculus 57-60 2228019-7 1990 Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection. Cyclosporine 25-28 CD4 antigen Mus musculus 321-324 2228019-7 1990 Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection. Cyclosporine 25-28 CD4 antigen Mus musculus 366-369 1452414-15 1992 Concurrently, anti-CD3-induced increases in the percentage of CD4+ and CD8+ cells cycling were inhibited by CsA. Cyclosporine 108-111 CD4 antigen Mus musculus 62-65 1903221-4 1991 Thymuses from the day-18 embryos exposed to CsA were partially depleted of CD4+CD8- single positive cells. Cyclosporine 44-47 CD4 antigen Mus musculus 75-78 35306230-3 2022 Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG. Cyclosporine 287-301 CD4 antigen Mus musculus 161-164 35306230-3 2022 Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG. Cyclosporine 303-306 CD4 antigen Mus musculus 161-164 28947964-9 2017 In particular, GAG could reverse a decline in CD4+FoxP3+ Tregs resulted from CsA treatments. Cyclosporine 77-80 CD4 antigen Mus musculus 46-49 2807375-12 1989 Together, these results demonstrate that resting CD4+ thymocytes can be induced to proliferation and lymphokine secretion by IL-2 alone in a process that is dependent on interaction with accessory cells, involves CD4 adhesion molecules and triggers activation through a CsA-sensitive pathway. Cyclosporine 270-273 CD4 antigen Mus musculus 49-52 2568932-2 1989 Defective thymic education of CD4 T helper cell function in cyclosporin A-treated mice. Cyclosporine 60-73 CD4 antigen Mus musculus 30-33 2660341-3 1989 A 10-day course of cyclosporine treatment inhibits the capacity of DA rats to reject PVG heart grafts and leads to the development of specific unresponsiveness and indefinite graft survival, which is mediated by a W3/25+ (CD4+) suppressor cell. Cyclosporine 19-31 CD4 antigen Mus musculus 222-225 2651520-3 1989 In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus. Cyclosporine 104-107 CD4 antigen Mus musculus 149-152 2651520-3 1989 In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus. Cyclosporine 104-107 CD4 antigen Mus musculus 162-165 2651520-6 1989 In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody. Cyclosporine 115-118 CD4 antigen Mus musculus 92-95 2651520-6 1989 In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody. Cyclosporine 115-118 CD4 antigen Mus musculus 92-95 2972933-4 1988 There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules. Cyclosporine 60-63 CD4 antigen Mus musculus 111-114 2972933-4 1988 There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules. Cyclosporine 60-63 CD4 antigen Mus musculus 143-146 2972933-4 1988 There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules. Cyclosporine 60-63 CD4 antigen Mus musculus 143-146 3136564-9 1988 Also, when we eliminate CD4 T cells from the diseased animals and graft islet tissue prior to the administration of cyclosporine, we are unable to maintain a graft with low-dose cyclosporine therapy. Cyclosporine 116-128 CD4 antigen Mus musculus 24-27 2531775-5 1989 A suboptimal dose of CsA was synergistic with an anti-CD4 mAb but not with an anti-CD8 antibody for whole MHC-mismatched grafts. Cyclosporine 21-24 CD4 antigen Mus musculus 54-57 2623737-4 1989 Thymuses from CsA-treated mice lacked the SP L3T4(CD4)+ subset, DN and double positive (DP) thymocytes were still present. Cyclosporine 14-17 CD4 antigen Mus musculus 50-53 26782505-8 2015 The CD4+ cell proportion decreased significantly (41.25 vs 69.22%, P < 0.01) and slightly (65.21 vs 69.22, P > 0.05) in the cyclosporine and sirolimus groups, respectively. Cyclosporine 130-142 CD4 antigen Mus musculus 4-7 21292993-0 2011 Accumulation of CD4+ T cells in the colon of CsA-treated mice following myeloablative conditioning and bone marrow transplantation. Cyclosporine 45-48 CD4 antigen Mus musculus 16-19 25808405-11 2015 Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs. Cyclosporine 75-87 CD4 antigen Mus musculus 104-107 23352844-13 2013 Collectively, our findings suggest that combination treatment of Glu and low-dose CsA leads to the therapeutic effects in Df-induced AD-like skin lesion in NC/Nga mice through inhibition of IgE, inflammatory cellular infiltrate, and recovery of skin barrier function via a mechanism that may inhibition of Th2-mediated immune responses, in part, increment of CD4(+)CD25(+) Treg cells. Cyclosporine 82-85 CD4 antigen Mus musculus 359-362 25714796-6 2015 CsA reduced the proportion of CD4(+) T cells and the level of IFN-gamma. Cyclosporine 0-3 CD4 antigen Mus musculus 30-33 25595785-9 2015 Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4(+) T cells and total ear residual cells. Cyclosporine 34-47 CD4 antigen Mus musculus 122-125 25452304-4 2015 In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival. Cyclosporine 3-6 CD4 antigen Mus musculus 225-228 25452304-4 2015 In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival. Cyclosporine 3-6 CD4 antigen Mus musculus 303-306 22613676-8 2012 In contrast to RPM and FTY720, MMF, LEF, CsA, and Cy markedly decreased the levels of Ag-specific CD4(+)KJ1-26(+)CD25(+)Foxp3(+) Tregs during immune response. Cyclosporine 41-44 CD4 antigen Mus musculus 98-101 22613676-10 2012 The stronger inhibiting effects of MMF, LEF, CsA and Cy on CD4(+)CD25(+)Foxp3(+) Tregs than on T effectors may block the host immune tolerance potentiality. Cyclosporine 45-48 CD4 antigen Mus musculus 59-62 22626517-8 2012 Mice treated with ciclosporin, which is both antiparasitic and immunosuppressive, have a milder, chronic, non-lethal infection and showed a significant reduction only in CD3(+) and CD4(+) T cell numbers. Cyclosporine 18-29 CD4 antigen Mus musculus 181-184 21292993-7 2011 This study demonstrates that, during the 21 days of immunosuppressive therapy, functional mechanisms are in place that result in increased homing of CD4(+) T effector cells to colons of CsA-treated mice. Cyclosporine 186-189 CD4 antigen Mus musculus 149-152 21292993-5 2011 Time-course studies revealed a significant increase in migration of CD4(+) T cells into the colon during CsA therapy, as well as significantly elevated mRNA levels of TNF-alpha, proinflammatory chemokines, and cell adhesion molecules in colonic tissue of CsA-treated animals compared with BMT controls, as early as day 14 post-BMT. Cyclosporine 105-108 CD4 antigen Mus musculus 68-71 21292993-6 2011 Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule. Cyclosporine 86-89 CD4 antigen Mus musculus 55-58 21292993-6 2011 Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule. Cyclosporine 147-150 CD4 antigen Mus musculus 55-58 20634434-1 2010 The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis. Cyclosporine 20-34 CD4 antigen Mus musculus 214-217 20634434-1 2010 The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis. Cyclosporine 36-39 CD4 antigen Mus musculus 214-217 21249305-0 2010 Cyclosporin A-treated dendritic cells may affect the outcome of organ transplantation by decreasing CD4+CD25+ regulatory T cell proliferation. Cyclosporine 0-13 CD4 antigen Mus musculus 100-103 20060322-6 2010 RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p < 0.001), markedly decreased CD4+ and CD8+ T cells (p < 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p < 0.005). Cyclosporine 109-121 CD4 antigen Mus musculus 197-200 20060322-6 2010 RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p < 0.001), markedly decreased CD4+ and CD8+ T cells (p < 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p < 0.005). Cyclosporine 109-121 CD4 antigen Mus musculus 262-265 17229932-6 2007 CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells. Cyclosporine 0-3 CD4 antigen Mus musculus 127-130 19193795-9 2009 In BCG-immune mice the resistance to VV infection and VV-induced CD4 T-cell IFN-gamma production were ablated by cyclosporine A, which inhibits signaling through the T-cell receptor. Cyclosporine 113-127 CD4 antigen Mus musculus 65-68 19575969-16 2009 J2 and CsA groups only showed a small number of CD4(+) and CD8(+) T-lymphocytes in the grafts. Cyclosporine 7-10 CD4 antigen Mus musculus 48-51 17351648-6 2007 Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments. Cyclosporine 68-80 CD4 antigen Mus musculus 127-130 17351648-9 2007 In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo. Cyclosporine 15-27 CD4 antigen Mus musculus 79-82